DOV Pharmaceutical, Inc. announced today additional Phase Ib results for DOV 21,947, its lead triple reuptake inhibitor for the treatment of depression and obesity.
From: biz.yahoo.com
DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical ...
Posted by Ruslan Abuzant at 9:03 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment